Compare DIOD & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DIOD | JANX |
|---|---|---|
| Founded | 1959 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | N/A | 2021 |
| Metric | DIOD | JANX |
|---|---|---|
| Price | $50.40 | $14.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | $58.00 | ★ $60.27 |
| AVG Volume (30 Days) | 390.1K | ★ 3.3M |
| Earning Date | 02-10-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.48 | N/A |
| EPS | ★ 1.38 | N/A |
| Revenue | ★ $1,429,793,000.00 | $10,000,000.00 |
| Revenue This Year | $14.41 | N/A |
| Revenue Next Year | $8.07 | N/A |
| P/E Ratio | $36.51 | ★ N/A |
| Revenue Growth | ★ 10.45 | N/A |
| 52 Week Low | $32.93 | $13.76 |
| 52 Week High | $67.12 | $61.59 |
| Indicator | DIOD | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 52.21 | 28.18 |
| Support Level | $49.62 | $13.82 |
| Resistance Level | $52.64 | $14.49 |
| Average True Range (ATR) | 1.47 | 0.61 |
| MACD | -0.02 | 0.08 |
| Stochastic Oscillator | 22.14 | 9.76 |
Diodes Inc is a manufacturer and supplier of high-quality application-specific products within the broad discrete, logic, analog, and mixed-signal semiconductor markets. It serves the customer electronics, computing, communications, industrial, and automotive markets. The Company's products include diodes; rectifiers; transistors; MOSFETs; GPP bridges; GPP rectifiers; protection devices; function-specific arrays; single gate logic; amplifiers and comparators; Hall-effect and temperature sensors; and power management devices, including LED drivers, AC-DC converters and controllers, DC-DC switching and linear voltage regulators, voltage references along with special-function devices, such as USB power switches, load switches, voltage supervisors, and motor controllers.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.